Does pravastatin increase chylomicron remnant catabolism in postmenopausal women with type 2 diabetes mellitus?

Clinical Endocrinology

Volumn 63, Issue 6, 2005, Pages 650-656

  Ng, T W K ^a   Watts, Gerald F ^a,g   Stuckey, B G A ^a,b   Ching, H L ^b   Chan, D C F ^a   Uchida, Y ^c   Sakai, N ^d   Yamashita, S ^d   Martins, I J ^e   Redgrave, T G ^a,f   Barrett, P H R ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c FUJIREBIO INC   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e EDITH COWAN UNIVERSITY   (Australia)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; CARBON 13; CHOLESTEROL; CHYLOMICRON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LATHOSTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BREATH ANALYSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; ISOTOPE LABELING; MASS SPECTROMETRY; MATHEMATICAL MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA CLEARANCE; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN DEGRADATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN B-48; APOLIPOPROTEINS B; BREATH TESTS; CARBON ISOTOPES; CHOLESTEROL; CHOLESTEROL, LDL; CHYLOMICRON REMNANTS; CHYLOMICRONS; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MASS SPECTROMETRY; METABOLIC CLEARANCE RATE; MIDDLE AGED; PRAVASTATIN; TRIGLYCERIDES;

EID: 28844444992     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2005.02396.x     Document Type: Article

References (35)

1. Hu, F.B., Stampfer, M.J., Solomon, C.G., Liu, S., Willett, W.C., Speizer, F.E., Nathan, D.M. & Manson, J.E. (2001) The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Archives of Internal Medicine, 161, 1717-1723.
2. Karpe, F., Steiner, G., Uffelman, K., Olivecrona, T. & Hamsten, A. (1994) Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis, 106, 83-97.
3. Dane-Stewart, C.A., Watts, G.F., Barrett, P.H.R., Stuckey, B.G.A., Mamo, J.C.L., Martins, I.J. & Redgrave, T.G. (2003) Chylomicron remnant metabolism studied with a new breath test in postmenopausal women with and without type 2 diabetes mellitus. Clinical Endocrinology, 58, 415-420.
4. Watts, G.F., Mamo, J.C.L. & Redgrave, T.G. (1998) Postprandial dyslipidaemia in a nutshell: food for thought. Australian and New Zealand Journal of Medicine, 28, 816-823.
5. Mamo, J.C.L. (1995) Atherosclerosis as a post-prandial disease. Metabolism, 2, 229-244.
6. Chait, A., Bierman, E.L. & Alberts, J.J. (1979) Low density lipoprotein receptor activity in cultured human skin fibroblasts: mechanisms of insulin-induced stimulation. Journal of Clinical Investigation, 64, 1309-1319.
7. Westerveld, H.T., Kock, L.A., van Rijn, H.J., Erkelens, D.W. & de Bruin, T.W.A. (1995) 17β-Estradiol improves postprandial lipid metabolism in postmenopausal women. Journal of Clinical Endocrinology and Metabolism, 80, 249-253.
8. Chan, D.C., Watts, G.F., Barrett, P.H.R., Martins, I.J., James, A.P., Mamo, J.C.L., Mori, T.A. & Redgrave, T.G. (2002) Effect of atorvastatin on chylomicron remnant metabolism in visceral obesity: a study employing a new stable isotope breath test. Journal of Lipid Research, 43, 706-712.
9. Bilheimer, D.W., Grundy, S.M., Brown, M.S. & Goldstein, J.L. (1983) Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proceedings of the National Academy of Sciences of the United States of America, 80, 4124-4128.
10. Santos, R.D., Sposito, A.C., Ventura, L.I., Cesar, L.A.M., Ramires, J.A.F. & Maranhao, R.C. (2000) Effect of pravastatin on plasma removal of a chylomicron-like emulsion in men with coronary artery disease. American Journal of Cardiology, 85, 1163-1166.
11. Goldberg, R.B., Mellies, M.J., Sacks, F.M., Moye, L.A., Howard, B.V., Howard, W.J., Davis, B.R., Cole, T.G., Pfeffer, M.A. & Braunwald, E. (1998) Cardiovascular events and their reduction with pravastatin in diabetic and glucose-tolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation, 98, 2513-2519.
12. Watts, G.F., Barrett, P.H.R., Marais, A.D., Dane-Stewart, C.A., Martins, I.J., Dimmitt, S.B. & Redgrave, T.G. (2001) Chylomicron remnant metabolism in familial hypercholesterolaemia studied with a stable isotope breath test. Atherosclerosis, 157, 519-523.
13. Redgrave, T.G., Watts, G.R, Martins, I.J., Barrett, P.H.R., Mamo, J.C.L., Dimmitt, S.B. & Marais, A.D. (2001) Chylomicron remnant metabolism in familial dyslipidaemias studied with a remnant-like emulsion breath test. Journal of Lipid Research, 42, 710-715.
14. Duane, W.C. (1995) Serum lathosterol levels in human subjects reflect changes in whole body cholesterol synthesis induced by lovastatin but not dietary cholesterol. Journal of Lipid Research, 36, 343-348.
15. Bjorkhem, I., Miettinen, T.A., Reihner, E., Ewerth, S., Angelin, B. & Einarsson, K. (1987) Correlation between serum levels of some cholesterol precursors and activity of HMG-CoA reductase in human liver. Journal of Lipid Research, 28, 1137-1143.
16. Kempen, H.J.M., Glatz, J.F.C., Gevers Leuven, J.A., van der Voort, H.A. & Katan, M.B. (1988) Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. Journal of Lipid Research, 29, 1149-1155.
17. Miettinen, T.A., Tilvis, R.S. & Kesaniemi, Y.A. (1990) Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. American Journal of Epidemiology, 131, 20-31.
18. 2 breath test to assess the metabolism of triglyceride-rich lipoprotein remnants in mice. Journal of Lipid Research, 39, 691-698.
19. Sakai, N., Uchida, Y., Ohashi, K., Hibuse, T., Saika, Y., Tomari, Y., Kihara, S., Hiraoka, H., Nakamura, T., Ito, S., Yamashita, S. & Matsuzawa, Y. (2003) Measurement of fasting serum apoB-48 levels in normolipidemic and hyperlipidemic subjects by ELISA. Journal of Lipid Research, 44, 1256-1262.
20. Nakajima, K., Saito, T., Tamura, A., Suzuki, M., Nakano, T. & Adachi, M. (1993) Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clinica Chimica Acta, 223, 53-71.
21. Cianflone, K., Bilodeau, M., Davignon, J. & Sniderman, A.D. (1990) Modulation of chylomicron remnant metabolism by an hepatic hydroxymethylglutaryl coenzyme A reductase inhibitor. Metabolism, 39, 274-280.
22. Sposito, A.C., Santos, R.D., Amancio, R.F., Ramires, J.A.F., Chapman, M.J. & Maranhao, R.C. (2003) Atorvastatin enhances the plasma clearance of chylomicron-like emulsions in subjects with atherogenic dyslipidemia: relevance to the in vivo metabolism of triglyceride-rich lipoproteins. Atherosclerosis, 166, 311-321.
23. 2 cells. Atherosclerosis, 161, 55-63.
24. Mohammadi, A., Macri, J., Newton, R., Romain, T., Dulay, D. & Adeli, K. (1998) Effects of atorvastatin on intracellular stability and secretion of apolipoprotein B in HepG2 cells. Arteriosclerosis, Thrombosis and Vascular Biology, 18, 783-793.
25. Watts, G.F., Chan, D.C., Barrett, P.H.R., O'Neill, F.H. & Thompson, G.R. (2003) Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome. International Journal of Obesity and Related Metabolic Disorders, 27, 862-865.
26. Chan, D.C., Watts, G.F., Barrett, P.H.R., O'Neill, F.H. & Thompson, G.R. (2003) Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome. Obesity Research, 11, 591-596.
27. Bearnot, H.R., Glickman, R.M., Weinberg, L. & Green, P.H.R. (1982) Effect of biliary diversion on rat mesenteric lymph apolipoprotein-I and high density lipoprotein. Journal of Clinical Investigation, 69, 210-217.
28. Hirano, M., Maeda, K., Hayashi, H., Kusuhara, H. & Sugiyama, Y. (2005) Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. Journal of Pharmacology and Experimental Therapeutics, 314, 876-882.
29. Reaven, G.M. & Chen, Y.-D. (1988) Role of insulin in regulation of lipoprotein metabolism in diabetes. Diabetes/Metabolism Reviews, 4, 639-652.
30. Mahley, R.W. & Innerarity, T.L. (1983) Lipoprotein receptors and cholesterol homeostasis. Biochimica et Biophysica Acta, 737, 197-222.
31. Battula, S.B., Fitzsimons, O., Moreno, S., Owens, D., Collins, P., Johnson, A. & Tomkin, G.H. (2000) Postprandial apolipoprotein B48- and B100-containing lipoproteins in type 2 diabetes: do statins have a specific effect on triglyceride metabolism? Metabolism, 49, 1049-1054.
32. Parhofer, K.G., Laubach, E. & Barrett, P.H.R. (2003) Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients. Journal of Lipid Research, 44, 1192-1198.
33. Innerarity, T.L. & Mahley, R.W. (1978) Enhanced binding by cultured human fibroblasts of apoE continuing lipoproteins as compared with low density lipoproteins. Biochemistry, 17, 1440-1447.
34. Martins, I.J., Hone, E., Chi, C., Seydel, U., Martins, R.N. & Redgrave, T.G. (2000) Relative roles of LDLr and LRP in the metabolism of chylomicron remnants in genetically manipulated mice. Journal of Lipid Research, 41, 205-213.
35. van Beek, A.P., de Ruijter-Heijstek, F.C., Erkelens, D.W. & de Bruin, T.W.A. (1999) Menopause is associated with reduced protection from postprandial lipemia. Arteriosclerosis, Thrombosis and Vascular Biology, 19, 2737-2741.